yxqi@tsmc.edu.cn。
李炳龙，E-mail：laysun@163.com
"],"authorList":[{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"于新祥","email":"2870395083@qq.com","zuoZheDiZhiL_en":["null;"],"name_en":"Xinxiang Yu"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"李琳琳","zuoZheDiZhiL_en":["null;"],"name_en":"Linlin Li"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"彭宁宁","zuoZheDiZhiL_en":["null;"],"name_en":"Ningning Peng"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"王玮琳","zuoZheDiZhiL_en":["null;"],"name_en":"Weilin Wang"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"李炳龙","email":"laysun@163.com","zuoZheDiZhiL_en":["null;"],"name_en":"Binglong Li"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"齐永秀","email":"yxqi@tsmc.edu.cn","zuoZheDiZhiL_en":["null;"],"name_en":"Yongxiu Qi"}],"authorNotesCommon_cn":["于新祥，betway必威登陆网址 （山东省医学科院）在读研究生，专业：药物分析，E-mail：2870395083@qq.com。"],"affList_en":["Shandong First Medical University & Shandong Medical College，Taian 271016，China"],"fundList_cn":["山东省中医药科技发展计划(2019-0350);betway必威登陆网址 学术提升计划(2019LJ003)"],"affList_cn":["betway必威登陆网址 （山东省医学科院），山东 泰安 271016"],"article":{"keywordList_cn":["幽门螺杆菌","四联疗法","研究进展"],"juan":"42","zhaiyao_cn":"

幽门螺杆菌是一种世界范围内人类感染的病原菌，能够引起胃肠道疾病并导致胃癌的发生，已被世界卫生组织国际癌症研究机构列为一类致癌物，因此根除Hp感染是临床医生不可避免的问题。随着根除Hp治疗方法的不断进步，当前临床一线治疗手段已经发展为四联疗法。本研究将以四联疗法为主探讨其治疗机制及最新联合治疗方法，为临床治疗提供一定的理论基础。

","endNoteUrl_en":"http://xuebao.sdfmu.edu.cn/EN/article/getTxtFile.do?fileType=EndNote&id=163","reference":"
1 秦娟文.幽门螺杆菌相关研究进展及预防护理现状［J］.中西医结合护理（中英文），2018，4（10）：209.
2 Yang G，Yang Z，Markus G，et al. Effect of Helicobacter pylori on gastrointestinal microbiota： a population-based study in Linqu，a high-risk area of gastric cancer［J］.Gut，2019：1.
3 方洒，李恕军.幽门螺杆菌根除药物研究进展［J］.人民军医，2017，60（05）：444.
4 孔祥晔，欧阳建东.益生菌辅助治疗幽门螺杆菌感染的研究进展［J］.世界最新医学信息文摘，2017，17（99）：63.
5 曾昭静，韦昭华.四联疗法治疗幽门螺杆菌感染致消化性溃疡的临床疗效及其安全性［J］.临床合理用药杂志，2019，12（15）：52.
6 Gao CP，Zhang D，Zhang T，et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection： An update based on a systematic review and meta-analysis.［J］. Helicobacter，2020，25（4）：1.
7 Zhang YW，Hu WL，Cai Y，et al.Outcomes of furazolidone-and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication［J］.World Journal of Gastroenterology，2018，24（40）：4596.
8 Hu L，Li HY，Chen WQ，et al. Ultrastructure Characteristics of Different Chinese Medicine Syndromes of Helicobacter pylori -Correlated Gastric Diseases［J］. Chinese Journal of Integrative Medicine，2019，25（12）：917.
9 赵琪，刘兴山.中西医治疗幽门螺杆菌研究进展［J］.世界最新医学信息文摘，2019，19（71）：104.
10 刘誉华.连花清幽饮联合四联疗法干预幽门螺旋杆菌的随机对照研究［J］.临床医药文献电子杂志，2019，6（67）：148.
11 金佳慧，黄卫青，金依萍，等.中西医结合抗胃幽门螺旋杆菌（Hp）感染的疗效观察［J］.中国医药指南，2019，17（29）：171.
12 王保健，梁华，顾文芬，等.清中汤加味配合西药治疗幽门螺杆菌相关性胃溃疡疗效评价［J］.四川中医，2018，36（08）：80.
13 邢国庆.中西医结合治疗幽门螺杆菌相关性消化性溃疡［J］.中国中医药现代远程教育，2019，17（16）：106.
14 张嘉璐，霍丽娟.中西药联合在根除幽门螺杆菌治疗中的作用［J］.中国微生态学杂志，2018，30（07）：862.
15 廖晓敏，卫金歧.益生菌治疗幽门螺杆菌感染的研究进展［J］.中国老年学杂志，2019，39（03）：744.
16 张俊璇，方超然，时鑫鑫，等.根除幽门螺杆菌治疗药物的研究进展［J］.医学综述，2020，26（02）：316.
17 詹云凯，易静，段志刚.益生菌预处理联合四联疗法治疗初治失败幽门螺杆菌感染的临床效果［J］.中国当代医药，2020，27（03）：65.
18 吴际，刘君君，李艳，等.益生菌联合铋剂四联疗法根除幽门螺杆菌的临床研究［J］.中国医药科学，2020，10（03）：70.
19 Kashyapi Chakravarty，Smriti Gaur. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection［J］. Current pharmaceutical biotechnology，2019，20（2）：137.
20 Wan ZC，Song LL，Hu L，et al. Helicobacter pylori infection is associated with diabetes among Chinese adults.［J］. Journal of diabetes investigation，2020，11（1）：199.
21 Yu L，Luo LS，Long XH，et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy： A randomized trial.［J］. Helicobacter，2019，24（4）：1.
22 张彧，吴东升，徐寅，等.基于文献研究的中西医结合治疗幽门螺杆菌相关性胃病中中药用药规律分析［J］.中国中药杂志，2019，44（22）：4985.
23 Zhu XL.Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication［J］.China Medical Abstracts（Internal Medicine），2018，35（03）：174.
24 唐宏伟.消化内镜联合四联疗法治疗胃溃疡患者的临床效果［J］.医疗装备，2020，33（04）：111.
25 邵方娴，李玉函，宋敏，等.注射用兰索拉唑在健康受试者体内的药代动力学研究［J］.药物分析杂志，2014，34（08）：1355.
26 Leiman David A.. Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care［J］. Clinical Gastroenterology and Hepatology，2020，18（5）：1028.
","bibtexUrl_cn":"//www.pitakata.com/xuebao/CN/article/getTxtFile.do?fileType=BibTeX&id=163","articleType":"research-article","abstractUrl_en":"http://xuebao.sdfmu.edu.cn/EN/10.3969/j.issn.2097-0005.2021.08.020","qi":"8","id":163,"nian":2021,"bianHao":"1632973012157-263613795","zuoZheEn_L":"Xinxiang Yu, Linlin Li, Ningning Peng, Weilin Wang, Binglong Li, Yongxiu Qi","juanUrl_en":"http://xuebao.sdfmu.edu.cn/EN/Y2021","clcIndexList_en":[{"code":"R573","text":""}],"shouCiFaBuRiQi":"2021-09-28","qiShiYe":"638","received":"2021-03-02","qiUrl_cn":"http://xuebao.sdfmu.edu.cn/CN/Y2021/V42/I8","lanMu_cn":"综述","pdfSize":"411","zuoZhe_CN":"于新祥(), 李琳琳, 彭宁宁, 王玮琳, 李炳龙(), 齐永秀()","risUrl_cn":"//www.pitakata.com/xuebao/CN/article/getTxtFile.do?fileType=Ris&id=163","title_cn":"四联疗法根除幽门螺杆菌的研究进展","doi":"10.3969/j.issn.2097-0005.2021.08.020","jieShuYe":"640","keywordList_en":["Helicobacter pylori","quadruple therapy","research progress"],"endNoteUrl_cn":"//www.pitakata.com/xuebao/CN/article/getTxtFile.do?fileType=EndNote&id=163","zhaiyao_en":"

Helicobacter pylori is a worldwide pathogen of human infection，which can cause gastrointestinal diseases and lead to the occurrence of gastric cancer. It has been listed as a kind of carcinogen by the InternationalAgency for Research on Cancer of the World Health Organization. Therefore， eradicating Hp infection is an inevitable problem for clinicians. With the continuous progress of Hp eradication treatment， the current clinical first-line treatment has developed into quadruple therapy. This study will focus on quadruple therapy，explore its therapeutic mechanism and the latest combined therapy，and provide a certain theoretical basis for clinical treatment.

","bibtexUrl_en":"http://xuebao.sdfmu.edu.cn/EN/article/getTxtFile.do?fileType=BibTeX&id=163","abstractUrl_cn":"http://xuebao.sdfmu.edu.cn/CN/10.3969/j.issn.2097-0005.2021.08.020","zuoZheCn_L":"于新祥, 李琳琳, 彭宁宁, 王玮琳, 李炳龙, 齐永秀","juanUrl_cn":"http://xuebao.sdfmu.edu.cn/CN/Y2021","lanMu_en":"Review","clcIndexList_cn":[{"code":"R573","text":""}],"qiUrl_en":"//www.pitakata.com/xuebao/EN/Y2021/V42/I8","zuoZhe_EN":"Xinxiang Yu(), Linlin Li, Ningning Peng, Weilin Wang, Binglong Li(), Yongxiu Qi()","risUrl_en":"http://xuebao.sdfmu.edu.cn/EN/article/getTxtFile.do?fileType=Ris&id=163","title_en":"Research progress of quadruple therapy for eradication of Helicobacter pylori","hasPdf":"true"},"authorNotes_cn":["于新祥，betway必威登陆网址 （山东省医学科院）在读研究生，专业：药物分析，E-mail：2870395083@qq.com。","齐永秀，E-mail：yxqi@tsmc.edu.cn。
李炳龙，E-mail：laysun@163.com
"],"authorList_en":[{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"于新祥","email":"2870395083@qq.com","zuoZheDiZhiL_en":["null;"],"name_en":"Xinxiang Yu"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"李琳琳","zuoZheDiZhiL_en":["null;"],"name_en":"Linlin Li"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"彭宁宁","zuoZheDiZhiL_en":["null;"],"name_en":"Ningning Peng"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"王玮琳","zuoZheDiZhiL_en":["null;"],"name_en":"Weilin Wang"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"李炳龙","email":"laysun@163.com","zuoZheDiZhiL_en":["null;"],"name_en":"Binglong Li"},{"zuoZheDiZhiL_cn":["Shandong First Medical University 【-逻*辑*与-】amp; Shandong Medical College，Taian 271016，China ;"],"deceased":false,"name_cn":"齐永秀","email":"yxqi@tsmc.edu.cn","zuoZheDiZhiL_en":["null;"],"name_en":"Yongxiu Qi"}]}">

Research progress of quadruple therapy for eradication of Helicobacter pylori

Xinxiang Yu, Linlin Li, Ningning Peng, Weilin Wang, Binglong Li, Yongxiu Qi

Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences››2021, Vol. 42››Issue (8): 638-640.

PDF(411 KB)
PDF(411 KB)
Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences ›› 2021, Vol. 42 ›› Issue (8) : 638-640. DOI: 10.3969/j.issn.2097-0005.2021.08.020
Review

Research progress of quadruple therapy for eradication of Helicobacter pylori

    Author information +
    History +

    Abstract

    Helicobacter pylori is a worldwide pathogen of human infection，which can cause gastrointestinal diseases and lead to the occurrence of gastric cancer. It has been listed as a kind of carcinogen by the InternationalAgency for Research on Cancer of the World Health Organization. Therefore， eradicating Hp infection is an inevitable problem for clinicians. With the continuous progress of Hp eradication treatment， the current clinical first-line treatment has developed into quadruple therapy. This study will focus on quadruple therapy，explore its therapeutic mechanism and the latest combined therapy，and provide a certain theoretical basis for clinical treatment.

    Key words

    Helicobacter pylori/quadruple therapy/research progress

    Cite this article

    EndNote

    Ris (Procite)

    Bibtex

    Download Citations
    Xinxiang Yu, Linlin Li, Ningning Peng, Weilin Wang, Binglong Li, Yongxiu Qi.Research progress of quadruple therapy for eradication of Helicobacter pylori[J]. Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences. 2021, 42(8): 638-640 https://doi.org/10.3969/j.issn.2097-0005.2021.08.020

    References

    1 秦娟文.幽门螺杆菌相关研究进展及预防护理现状［J］.中西医结合护理（中英文），2018，4（10）：209.
    2 Yang G，Yang Z，Markus G，et al. Effect of Helicobacter pylori on gastrointestinal microbiota： a population-based study in Linqu，a high-risk area of gastric cancer［J］.Gut，2019：1.
    3 方洒，李恕军.幽门螺杆菌根除药物研究进展［J］.人民军医，2017，60（05）：444.
    4 孔祥晔，欧阳建东.益生菌辅助治疗幽门螺杆菌感染的研究进展［J］.世界最新医学信息文摘，2017，17（99）：63.
    5 曾昭静，韦昭华.四联疗法治疗幽门螺杆菌感染致消化性溃疡的临床疗效及其安全性［J］.临床合理用药杂志，2019，12（15）：52.
    6 Gao CP，Zhang D，Zhang T，et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection： An update based on a systematic review and meta-analysis.［J］. Helicobacter，2020，25（4）：1.
    7 Zhang YW，Hu WL，Cai Y，et al.Outcomes of furazolidone-and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication［J］.World Journal of Gastroenterology，2018，24（40）：4596.
    8 Hu L，Li HY，Chen WQ，et al. Ultrastructure Characteristics of Different Chinese Medicine Syndromes of Helicobacter pylori -Correlated Gastric Diseases［J］. Chinese Journal of Integrative Medicine，2019，25（12）：917.
    9 赵琪，刘兴山.中西医治疗幽门螺杆菌研究进展［J］.世界最新医学信息文摘，2019，19（71）：104.
    10 刘誉华.连花清幽饮联合四联疗法干预幽门螺旋杆菌的随机对照研究［J］.临床医药文献电子杂志，2019，6（67）：148.
    11 金佳慧，黄卫青，金依萍，等.中西医结合抗胃幽门螺旋杆菌（Hp）感染的疗效观察［J］.中国医药指南，2019，17（29）：171.
    12 王保健，梁华，顾文芬，等.清中汤加味配合西药治疗幽门螺杆菌相关性胃溃疡疗效评价［J］.四川中医，2018，36（08）：80.
    13 邢国庆.中西医结合治疗幽门螺杆菌相关性消化性溃疡［J］.中国中医药现代远程教育，2019，17（16）：106.
    14 张嘉璐，霍丽娟.中西药联合在根除幽门螺杆菌治疗中的作用［J］.中国微生态学杂志，2018，30（07）：862.
    15 廖晓敏，卫金歧.益生菌治疗幽门螺杆菌感染的研究进展［J］.中国老年学杂志，2019，39（03）：744.
    16 张俊璇，方超然，时鑫鑫，等.根除幽门螺杆菌治疗药物的研究进展［J］.医学综述，2020，26（02）：316.
    17 詹云凯，易静，段志刚.益生菌预处理联合四联疗法治疗初治失败幽门螺杆菌感染的临床效果［J］.中国当代医药，2020，27（03）：65.
    18 吴际，刘君君，李艳，等.益生菌联合铋剂四联疗法根除幽门螺杆菌的临床研究［J］.中国医药科学，2020，10（03）：70.
    19 Kashyapi Chakravarty，Smriti Gaur. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection［J］. Current pharmaceutical biotechnology，2019，20（2）：137.
    20 Wan ZC，Song LL，Hu L，et al. Helicobacter pylori infection is associated with diabetes among Chinese adults.［J］. Journal of diabetes investigation，2020，11（1）：199.
    21 Yu L，Luo LS，Long XH，et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy： A randomized trial.［J］. Helicobacter，2019，24（4）：1.
    22 张彧，吴东升，徐寅，等.基于文献研究的中西医结合治疗幽门螺杆菌相关性胃病中中药用药规律分析［J］.中国中药杂志，2019，44（22）：4985.
    23 Zhu XL.Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication［J］.China Medical Abstracts（Internal Medicine），2018，35（03）：174.
    24 唐宏伟.消化内镜联合四联疗法治疗胃溃疡患者的临床效果［J］.医疗装备，2020，33（04）：111.
    25 邵方娴，李玉函，宋敏，等.注射用兰索拉唑在健康受试者体内的药代动力学研究［J］.药物分析杂志，2014，34（08）：1355.
    26 Leiman David A.. Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care［J］. Clinical Gastroenterology and Hepatology，2020，18（5）：1028.
    PDF(411 KB)

    Accesses

    Citation

    Detail
    Sections
    Recommended
    Copyright © Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences, All Rights Reserved.
    Tel: 0531-59556323；59556325　
    E-mail：6719xb@163.com
    Powered by Beijing Magtech Co. Ltd,.

    /

    〈 〉